Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations

Related Articles

Applied Digital's AI Ambition: Can Q4 Earnings Justify the Multi-Billion Dollar Bet?

1 months ago

Why is Laurus Investment Counsel Making a Multi-Billion Dollar Bet on Microsoft

5 months ago

AMD's Anthropic Bet: A Multi-Billion-Dollar Validation with a Valuation Catch

1 months ago

What Does This Multi-Billion Dollar Project Mean for SmartGrid Innovations' Revenue Growth

4 months ago

Category

You may also like

Stock News•1 week ago

AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah

AstraZeneca's Etcamah received accelerated FDA approval for advanced breast cancer, after a 56% risk reduction in progression or death versus comparator. The therapy targets certain patients with limi...

AZN

Share

Stock News•1 months ago

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity's REVTORPYK/gedatolisib gained FDA approval and NCCN Category 1 inclusion, de-risking adoption. SG&A surged for launch, but a $754M cash position funds operations into 2029, supporting a pote...

CELC

Share

Stock News•1 months ago

Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment

Replimune Group Inc. (NASDAQ:REPL) secured FDA accelerated approval for Tudriqev, an oncolytic immunotherapy for skin cancer, after two prior rejections. The approval could unlock commercial revenue a...

REPL

Share